PL4192872T3 - Białka wiążące nkg2d, cd16 i egfr - Google Patents

Białka wiążące nkg2d, cd16 i egfr

Info

Publication number
PL4192872T3
PL4192872T3 PL21762272.9T PL21762272T PL4192872T3 PL 4192872 T3 PL4192872 T3 PL 4192872T3 PL 21762272 T PL21762272 T PL 21762272T PL 4192872 T3 PL4192872 T3 PL 4192872T3
Authority
PL
Poland
Prior art keywords
egfr
proteins binding
binding nkg2d
nkg2d
proteins
Prior art date
Application number
PL21762272.9T
Other languages
English (en)
Inventor
Ann F. CHEUNG
Stacey V. DRABIC
Asya Grinberg
Zong Sean Juo
Katia LIHARSKA
Christopher Ryan MORGAN
Nicolai Wagtmann
Original Assignee
Dragonfly Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics, Inc. filed Critical Dragonfly Therapeutics, Inc.
Publication of PL4192872T3 publication Critical patent/PL4192872T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL21762272.9T 2020-08-05 2021-08-05 Białka wiążące nkg2d, cd16 i egfr PL4192872T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063061510P 2020-08-05 2020-08-05
PCT/US2021/044737 WO2022031965A1 (en) 2020-08-05 2021-08-05 Proteins binding nkg2d, cd16 and egfr

Publications (1)

Publication Number Publication Date
PL4192872T3 true PL4192872T3 (pl) 2025-08-11

Family

ID=77519840

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21762272.9T PL4192872T3 (pl) 2020-08-05 2021-08-05 Białka wiążące nkg2d, cd16 i egfr

Country Status (14)

Country Link
US (1) US20230257467A1 (pl)
EP (2) EP4585611A3 (pl)
JP (2) JP7575501B2 (pl)
KR (1) KR20230042519A (pl)
CN (1) CN117730096A (pl)
AU (1) AU2021320311A1 (pl)
BR (1) BR112023002116A2 (pl)
CA (1) CA3188215A1 (pl)
ES (1) ES3031307T3 (pl)
IL (1) IL300249A (pl)
MX (1) MX2023001555A (pl)
PL (1) PL4192872T3 (pl)
WO (1) WO2022031965A1 (pl)
ZA (1) ZA202301445B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
US20230250176A1 (en) * 2022-02-09 2023-08-10 Dragonfly Therapeutics, Inc. Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16
WO2024035662A2 (en) * 2022-08-10 2024-02-15 Merck Sharp & Dohme Llc Proteins binding nkg2d, cd16, and ceacam5

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
SG10201913680PA (en) * 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
EP3258967A4 (en) 2015-02-20 2018-10-03 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
PH12022553648A1 (en) * 2015-09-25 2024-03-11 Genentech Inc Anti-tigit antibodies and methods of use
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
US20200216544A1 (en) * 2017-08-16 2020-07-09 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor

Also Published As

Publication number Publication date
EP4585611A3 (en) 2025-12-10
EP4192872A1 (en) 2023-06-14
EP4585611A2 (en) 2025-07-16
CN117730096A (zh) 2024-03-19
KR20230042519A (ko) 2023-03-28
CA3188215A1 (en) 2022-02-10
JP2023536567A (ja) 2023-08-28
EP4192872B1 (en) 2025-04-16
ES3031307T3 (en) 2025-07-07
EP4192872C0 (en) 2025-04-16
BR112023002116A2 (pt) 2023-04-25
JP2025011276A (ja) 2025-01-23
AU2021320311A1 (en) 2023-03-02
ZA202301445B (en) 2025-07-30
MX2023001555A (es) 2023-03-08
WO2022031965A1 (en) 2022-02-10
IL300249A (en) 2023-03-01
JP7575501B2 (ja) 2024-10-29
US20230257467A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
EP4146271A4 (en) PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
IL292261A (en) Proteins that bind nkg2d, cd16 and flt3
IL280656A (en) Multispecific binding proteins that bind HER2, NKG2D, and CD16 and methods of use
IL281305A (en) Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1
SG11202101294RA (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
SG11202011139YA (en) Protein binding nkg2d, cd16 and a fibroblast activation protein
IL273067A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
EP3755721A4 (en) MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16, AND METHODS OF USE
IL268790A (en) CD33, NKG2D and CD16 binding proteins
EP3681532A4 (en) NKG2D, CD1 6 AND TYPE LECTIN LIKE MOLECULE 1 (CLL-1) BINDING PROTEINS
IL272706A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
IL270801A (en) NKG2D, CD16 and tumor-associated antigen binding protein
IL268755A (en) Proteins binding her2, nkg2d and cd16
SG11202101298XA (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
SG11202000632QA (en) Proteins binding nkg2d, cd16 and flt3
IL268768A (en) Proteins binding gd2, nkg2d and cd16
IL268574A (en) proteins that bind psma, nkg2d, and cd16
EP3583132A4 (en) PROTEINS THAT BIND CD123, NKG2D AND CD16
EP4192872C0 (en) PROTEINS BINDING TO NKG2D, CD16 AND EGFR
IL318770A (en) NKG2D, CD16, and CEACAM5 binding proteins
HK40087410A (en) Proteins binding nkg2d, cd16 and egfr
HK40085796A (en) Proteins binding nkg2d, cd16 and clec12a
HK40120836A (en) Proteins binding nkg2d, cd16, and ceacam5
HK40076267A (en) Proteins binding nkg2d, cd16 and flt3
HK40114779A (en) Proteins binding nkg2d, cd16 and baff-r